Drug Profile
Zeteletinib - Boston Pharmaceuticals
Alternative Names: BOS 172738; BOS172738 adipate; CAXM-1190b; DS-5010; DS-5010b; Zeteletinib adipateLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Boston Pharmaceuticals; Daiichi Sankyo Company
- Class Acetamides; Antineoplastics; Ethers; Fluorinated hydrocarbons; Oxazoles; Pyridines; Quinolines; Small molecules
- Mechanism of Action Proto oncogene protein c ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Belgium (PO, Capsule)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in France (PO, Capsule)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Hong Kong (PO, Capsule)